39977-05-4

Basic information

• Product Name: 5-(2-chlorophenyl)-7-ethyl-3-hydroxy-1-methyl-1,3-dihydro-2H-thieno[2,3-e][1,4]diazepin-2-one
• Synonyms: 5-(2-chlorophenyl)-7-ethyl-3-hydroxy-1-methyl-1,3-dihydro-2H-thieno[2,3-e][1,4]diazepin-2-one
• CAS NO: 39977-05-4
• Molecular Weight: 334.826
• Mol File: 39977-05-4.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 5-(2-chlorophenyl)-7-ethyl-3-hydroxy-1-methyl-1,3-dihydro-2H-thieno[2,3-e][1,4]diazepin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(2-chlorophenyl)-7-ethyl-3-hydroxy-1-methyl-1,3-dihydro-2H-thieno[2,3-e][1,4]diazepin-2-one(39977-05-4)
• EPA Substance Registry System: 5-(2-chlorophenyl)-7-ethyl-3-hydroxy-1-methyl-1,3-dihydro-2H-thieno[2,3-e][1,4]diazepin-2-one(39977-05-4)

Safety Data

• Hazardous Substances Data: 39977-05-4(Hazardous Substances Data)

Upstream product

• 33671-46-4 clotiazepam 

Downstream Products

• 153193-59-0 (5-(2-chlorophenyl)-7-ethyl-1-methyl-2-oxo-1,3-dihydro-2H-thieno[2,3-e][1,4]diazepin-3-yl)-N-(3-methylphenyl)carbamate 

Relevant articles and documents

Therapeutic agent for osteoporosis and diazepine compound

A therapeutic agent for osteoporosis, comprising an azepine compound of the formula STR1 wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof as an active ingredient, a method for treating osteoporosis comprising administering said compound and a use of said compound for the production of a therapeutic agent for osteoporosis. The compounds of the formula (I) have superior bone resorption-inhibitory activity and act to reduce the increased amount of calcium in blood serum, which is caused by bone resorption. Accordingly, these compounds are usable as pharmaceutical agents to effectively inhibit bone resorption, to prevent decrease of bone mass and to prevent or suppress the increase of calcium amount in blood serum which is caused by the progress of bone resorption, with regard to Paget's disease, hypercalcemia, osteoporosis and so on in which the progress of bone resorption is considered to be deeply associated with the symptom, and to the symptoms of progressing bone resorption (development into osteoporosis) along with inflammatory joint diseases such as rheumatoid arthritis.